Timmerman, John <br/><br/>
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.  [electronic resource] 

 -  American journal of hematology  05 2020 
 - 510-520 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-8652 
<br/><br/><label>Standard No.: </label>10.1002/ajh.25757  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--pharmacokinetics<br/>Antineoplastic Agents, Immunological--pharmacology<br/>Female<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Progression-Free Survival<br/>Rituximab--pharmacokinetics